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A B S T R A C T
The psychopathological dynamics in suicidality overcomes actual diagnostic distribution therefore pharmacotherapy
has restricted role in overall prevention of suicidal behaviour among mentally ill and is demanding for clinician. This
role is achieved through reduction and alleviation of suicidal risk with rational and individual pharmacotherapeutic
approach emphasising effective, safe and tolerable treatment. The genetic and epigenetic factors, dysfunction of neuro-
transmitter, neuroendocrine system and stress response system has been determining for neurobiology of suicidality.
Therefore, pharmacotherapeutic approach should be focused, not only on prevention and reduction of suicidality, but ad-
justed for general and diagnosis-specific risk factors. Suicidality represents trans-diagnostic issue, however making the
correct diagnosis is of great importance. Identical group of psychiatric medications or even the same drug, could be palli-
ating for suicidal behaviour in one diagnostic category and in other aggravating concerning suicidal ideations. Clini-
cian should be reserved towards epidemiological studies about reducing suicidal rate due to increased consumption of
antidepressants. Detailed data analysis showed there is no relevancy which antidepressants were given to specific pa-
tient, in what age and phase of illness. The FDA has issued warnings about possible increased risk of suicidal behaviour
in children and adolescents when given antidepressant therapy. In general, serotoninergic drugs have neutral or mildly
protective effect on potential suicidal behaviour while noradrenergic drugs may have activating effect or could even
worsen suicidal ideation in certain phase of the illness. When given in appropriate dose and the right time, dual or
noradrenergic antidepressants, could also have good protective impact on specific patient. In patients with bipolar disor-
der, antidepressive drug could be trigger for suicidal behaviour. Greater susceptibility when diagnosing bipolar disorder
and broader usage of mood stablizing medications, alone or combined with other psychopharmacotherapy, has the sig-
nificant role in suppression and elimination of suicidal behaviour. The lithium and sodium valproate are found to be
particularly suitable for prevention and elimination of suicidal behaviour along with some other mood stabilizers. Phar-
macohterapy of suicidality in patients with schizophrenia represents specific problem. Confirmed drug with anti-suici-
dal effect, clozapine, is not first choice medication and does not represent general solution for suicidality in schizophrenia. For
clinician, the pharmacotherapy of suicidal behaviour consists of skilled individual and rational drug administration ac-
companied with appropriate psychotherapeutic support.
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Introduction
There is no unique theory or therapeutic method de-
signed for prevention or elimination of suicidal behav-
iour. The fact how 90% suicide victims have had diagnos-
ed permanent or temporary psychiatric disorder could
not be omitted1. Suicidal behaviour has been frequently
related with these mental disorders: major depression,
schizophrenia, bipolar disorder and associated comorbid
states. Pharmacotherapeutic measures are being focused
on prevention of suicidal ideas, behaviours and elimina-
tion of existing suicidality avoiding the act of suicide.
Therefore, the pharmacotherapy of suicidal behaviour
represents secondary prevention2. Psychopathology of
suicidality has gone beyond diagnostic classification and
has had simultaneously intersected and annihilated di-
mensions of human existence – spiritual, social and bio-
logical. For clinician, pharmacotherapy of suicidal behav-
iour is being particulary demanding and has limited role
in overall suicide prevention for various mental disor-
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ders. With rational and individually adjusted pharmaco-
therapy focused on efficient, safe and tolerable treat-
ment, the role in alleviating and reducing the suicide risk
is being accomplished3,4. Also, the genetic and epigenetic
factors, dysfunction of neurotransmitter and neuroen-
drocine system, stress response system have determined
the neurobiology of suicidality and should be taken into
account. Regardless the psychiatric disorder, the neuro-
biology differs from one individual to another5,6. Phar-
macotherapeutic approach focused on prevention and
elimination of suicidality should also consider general
and diagnosis specific risk factors. The most significant
overall risk factors for possible suicidal behaviour among
mentally ill are: age under 45 years old, therapeutic re-
sistance, previous hospitalizations, history of suicide
among relatives, previous suicide attempts, akathisia,
despair, comorbid personality disorder with pronounced
features such as impulsivity, aggression and rigidity in
thinking. The specific risk factors are being affiliated
with diagnosis of mental disorder, specific pharmaco-
therapy and specific interaction of patient with sur-
roundings7. The suicidal behaviour, in this article, has
been comprehended according to guidelines of Columbia
classification algorithm for suicide assessment (C-CASA)
like: suicidal attempts, preparations for suicide as well as
active or passive thinking about suicide without immedi-
ate preparations for realisation8,9.
Depression
There is no exclusive connection of suicidal behaviour
and suicide with particular diagnostic category, however,
the treatment of suicidal behaviour is mostly focused on
depressive symptoms. High risk features for suicide are
found to be: impulsivity, hostility, anxiety, despair, agita-
tion, anhedony, insomnia, panic attacks, hypersensibility,
stress susceptibility, cognitive impairment with certain
neurobiological (low serotinine level) and genetic charac-
teristics (gene variations for BDNF and it´s receptor
NTRK2)10–13. Besides mentioned characteristics, the neg-
ative life events and circumstances with depressive po-
tential and other psychosocial environmental risk factors
have influenced suicidal on behaviour14. Greatest expec-
tations in pharmacologic prevention and treatment of
suicidal behaviour are being directed on antidepressants.
Clinical and epidemiologic research studies have resulted
in multiple controversial reports about anti-suicidal po-
tential of antidepressants in general and drug specific.
Some reports confirmed beneficial effect of wide-range
antidepressant usage on suicide rate reduction in some
developed countires14. Based on the contrary reports, the
supervisor authority for drug transportation have been
alarming for caution when applying antidepressants, es-
pecially in younger population. According to Carlsten et
all. (2001) report, the suicide rate in Sweden was reduced
in time period from 1977 to 1979 and from 1995 to 1997
compared with increased antidepressant consumption15.
Research in Australia (Hall et al., 2003.) and Hungary
(Rihmer et al., 2000.) had given similar results, but still,
none direct relation between antidepressant effect on re-
duced suicide rate in those countries was not deter-
mined. For example, in Sweden the usage of antidepres-
sants has grown in elderly and suicide rates reduction
has been found in younger population15. In Australia, the
consumption of antidepressants was increased in all age
groups, however, the downfall in suicide rate have been
reported only among the elderly16. Gibbons et al. (2005)
had researched data on completed suicides in USA dur-
ing years 1996–1998 and there was no relation between
antidepressant usage and suicide rate in general and in
separate counties17. The correlation was found when
considering only the SSRI and new generation of antide-
pressants. Increased consumption of antidepressants re-
sulted in decline of suicide rates in and among counties.
Higher suicide rate was recorded with tryciclic antide-
pressants (TCAs) but not equally in every county. Higher
suicide rates and increased usage of tryciclic antidepres-
sants was registered in countries with poorly organized
health service and with lower socio-economical status,
but this was doubtful due to mentioned various demo-
graphic and socio-economical factors17. Contrary to these
positive reports, there are numerous reports about in-
creased suicidal risk related to antidepressants. Rhimer
et al. (2008)18, have done meta-analysis of controlled clin-
ical studies and found moderately increased risk for sui-
cidal behaviour in patients taking antidepressants com-
pared to those on placebo. This result had probably been
marked by limitations of these studies when compared to
researched parameters and given research protocols
which complicated the flexibile therapeutic approach (early
drop-out of patients on placebo, monotherapy, masked bi-
polar depressions). Certain randomized controlled stud-
ies openly doubt the efficacy of antidepressants on sui-
cide risk reduction19,20. Increased suicide rate reports of
depressive patients taking SSRIs and other antidepres-
sants compared to placebo have motivated the WHO and
FDA, to issue a warning for clinicians regarding careful
usage of antidepressants during first weeks of therapy
due to higher suicide risk. These warnings have reflected
on prescribing antidepressants in practice which could
have paradoxically increase suicide risk in depressive
patients21. In addition, recent meta-analysis of 372 dou-
ble-blind, randomized and placebo controlled studies en-
compassing 99.231 depressive adults have shown there is
undoubtedly lower risk in depressive persons treated
with antidepressants in comparison to individuals on
placebo. The tendency towards moderate risk increase
has been registered among population under 25 years
old, and this might be only possible exception22. Research
results of Danish suicide register and prescribed antide-
pressants register have contributed to positive impact of
antidepressants on suicide risk reduction. According to
results of one Danish study, only 10% of depressive per-
sons who had committed suicide were treated with anti-
depressant one month before suicide23. The meta-analy-
sis of 8 large observational studies (Barbui et al., 2009.),
encompassing 200.000 patients, have found SSRIs re-
duce suicide risk and suicidal behaviour in adults, how-
ever, the suicide risk has been found to be twice greater
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in adolescents24. The short term efficacy studies for spe-
cific new generation antidepressants (SSRIs) mostly
state there is no increased risk of suicidal behaviour,25,26
moreover the risk is reduced27,28. Even when moderaetly
increased risk for SNRIs (venlafaxin) exists, this is ex-
plained with limitations of the study and the fact that
venlafaxine was used to treat patients with refractory de-
pression and comorbidity29. In conclusion, the antide-
pressants in general, especially SSRIs, if being correctly
applied, reduce the suicidal risk. Solely, the pharma-
cotherapy of suicidal behaviour in depressive individuals
could not have been adequate if it was not correctly diag-
nosed and were not considered other factors for suicidal
behaviour. The antidepressant treatment could not be
successful without proper psychoeducation and psycho-
therapeutic support along with treatment of comorbid
states and full remission maintanace10. When all criteria
have been satisfied and with carefully selected antide-
pressant, based on principles of individually adjusted
therapy30, the efficiency of antidepressants in reduction
of suicidal behaviour becomes undoubtful. The caution
has been recommended during first weeks of treatment
because of uneven antidepressant efficiency on particu-
lar aspects of depressive disorder or even pharmacologi-
cally potentiated effect to specific suicide features. Due
to repetitive research results about increased suicidal
risk, the special caution has been suggested while treat-
ing children and adolescents in the first months of ther-
apy. For this reason, in year 2004, the manufacturers of
antidepressants have been given order from FDA to ex-
cerpt a drug declaration warning for professionals on in-
creased suicidal risk for children and adolescents. The
American Psychiatric Association (APA) has responded
that antidepressants save human lives and is recom-
mended to treat children and adolescents with antide-
pressants due their favourable effect than deprive them
for such treatment. The Texas algorithm for child treat-
ment has (supplemented in year 2006) recommended the
SSRIs as a first choice during first and second treatment
attempt31. In case the child has not shown adequate im-
provement on second SSRI, then could be considered
other categories of antidepressants could be considered.
It is also mentioned how combination of two antidepres-
sants, antidepressant and anxiolytics (especially at the
beginning of treatment) or some other supportive strate-
gies could enhance the therapeutic response32,33.
Schizophrenia
Patients with schizophrenia often share many risk
factors with general population and persons with other
mental disorders. They often commit suicide under influ-
ence of symptoms of primary disease and comorbid states
and because of that pharmacotherapy represents signifi-
cant support in prevention and elimination of suicidal
behaviour34,35. Neurobiological predictors of suicidality,
common to other psychiatric disorders, have been basis
for pharmacotherapy of suicidal behaviour in schizophre-
nia and could be amended with such therapy. These pre-
dictors are: low serotonin level in central nervous system
and low level of serotonin metabolites in cerebrospinal
fluid, decreased binding of radioactive marked ligands on
pre-synaptic serotonine receptors in frontal cortex and
increased density of post-synaptic 5-HT2 receptors in the
same brain areas. This serotonin disbalance in central
nervous system predisposes primarily impulsive and ag-
gressive behaviour than suicide itself36. Recently, the role
of gene polymorphism is being researched, particularly
genes regulating dopamine transport in patients with
schizophrenia and suicidal behaviour37. Still, there are
many steps to be made in order to complete the neuro-
biology circle of suicidality in schizophrenia. For this rea-
son, the pharmacologic prevention and therapy has been
relying mostly on principles of good clinical practice
while treating this disorder and comorbid states. These
principles have been appreciative towards early diagnos-
ing and treating schizophrenia, appliance of effective and
tolerable antipsychotics, patient education about the ill-
ness and pharmacotherapeutic agents, the assurance of
compliance and patient supervision during acute phase
treatment and after hospital discharge with psychothe-
rapeutic and psychosocial support in order to protect the
patient from further stress34,38,39. Implementation of these
general measures could significantly reduce suicidal risk
and create supportive envirnoment for additional effi-
cacy of medications. The discrepancies in appliance of
these measures are being preclusive for statisti- cally ob-
vious advantage of certain psychopharmacs on suicidal
behaviour reduction in schizophrenia. Some research shows
there is no certain evidence about efficacy of second gen-
eration antipsychotics in preventing suicidal behaviour
in schizophrenia when compared to first generation anti-
psychotics40. The pharmacodynamic characteristics of
second generation antipsychotics have ensured: good ef-
ficiency, the dopamine-serotonin concept of action with
less akathisia and iatrogenically induced depression,
better affective stability and cognitive functioning ac-
companied by better tolerability and compliance. This,
with all the other measures for prevention and therapy
of suicidal behaviour in schizophrenia, has represented
additional significant contribution for suicidal risk re-
duction41. However, the clozapine has been recognized as
exception regarding anti-suicidal potential. The study of
Meltzer and Okayli (1995) first has shown clozapine re-
duced suicidal risk in patients with schizophrenia42. Aim
of the research was to identify whether clozapine therapy
reduces suicidality in treatment resistant patients with
schizophrenia and schizoaffective disorder. The cloza-
pine had been administred during hospitalisation with
average dose of 500 miligrams. When the 2 years period
before treatment with clozapine has been compared to
period of 2 year treatment with this drug, the reduction
of suicidal attempts for 86% during treatment was found.
Large two-year multricentric, randomized, prospective,
single-blind InterSePT study (The International Suicide
Prevention Trial) in which have been compared anti-sui-
cidal effect of clozapine (300–900 mg/ daily) and olan-
zapine (10–20 mg/daily) confirmed clozapine efficiency in
reduction of suicidal risk34,43. Meltzer presumed, the fa-
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vourable anti-suicidal effect of clozapine could be ex-
plained with stabilization of biogenic amines transport in
prefrontal cortex because the imbalance of these amines
represented the biological basis of suicidality. Clinically,
the clozapine has anti-agressive and antidepressive ef-
fect, it rarely causes akathisia and is well tolerated there-
fore has been recommended as first choice medication for
prevention of suicide in schizophrenia. Based on Inter
SePT research results, the FDA has approved new indi-
cation for clozapine – recurrent suicidal behaviour for
patients with schizophrenia and schizoaffective disorder.
This was the first time FDA approved medication with
indication for suicidality. Previously regulated commit-
ment of periodic white blood cells monitoring has re-
mained. Reduction of suicidal risk requires particular
skill in treating other comorbid disorders in schizophre-
nia, most often affective, due caution needed when apply-
ing anxiolitycs, antidepressants and mood stabilizing
medications. Finally, the most important aspect of sui-
cide risk reduction in schizophrenia lies in well chosen
and individually adjusted therapy although pharmaco-
therapy alone should not be the only support during
treatment. It is necessary to become acquainted with pa-
tient´s surroundings, medical history, his expectations
and expectations of his enviroment in order to ensure the
life worth living aided by psychotherapy, psychosocial
support and other interventions34.
Bipolar Disorder
The bipolar disorder is diagnostic category with the
greatest suicidal risk. The estimations have shown that
25–30% of individuals with bipolar disorder would have
suicide attempt and every fifth individual would commit
suicide during lifetime44. Suicide risk is over 20 time
greater than in general population45. Acceptance of dis-
tended diagnostic criteria in diagnosing specific subtypes
of bipolar disorder (Bipolar disorder I = manic-depres-
sive disorder, Bipolar disorder II = depression with spon-
taneous hypomania and Bipolar disorder spectrum = de-
pression + bipolar predictors)46, has revealed the life
burdened with severe suicidal risk in this disorder and
explications of some authors on increased suicidal risk
during antidepressant therapy have been recognized. Us-
age of antidepressants in bipolar disorder could be a trig-
ger for unwanted and uncontrolled affective changes
which might even result in agitation and suicide realiza-
tion. The distended diagnosing of bipolar disorder (bipo-
lar I and bipolar II) and especially bipolar spectrum sub-
type has burdened this disorder with increased suicidal
risk. This diagnostic category now comprehends signifi-
cant number of depressive episodes + diagnosis of bipo-
lar depression in first relatives, antidepressant induced
mania or hypomania, hyperthymic or cyclothymic tem-
perament, recurrent severe depression episodes (>3),
brief severe depressive episodes (on average, <3 monthly),
atypical symptoms of depression and severe psychotic de-
pressive episodes, early onset of severe depressive epi-
sode (<25 year old), postpartum depression, seasonal de-
pression, rapid cycling behaviour pattern, unstable mood,
inefficiency of antidepressants (only acute response, in-
stead prophylactic one), absence of therapeutic response
on three or more antidepressants, mixed depression (psy-
chomotor agitation, irritability, verbiage), drug abuse46,47.
In these mentioned states, antidepressants should be
given in combination with mood stabilizing drugs. The
selective serotonin reuptake inhibitors have been consid-
ered as particularly safe48. During acute phase of illness
the suicidal risk is especially high and some predictive
factors are: stressful life events, hazardous behaviour in
bipolar I (often car accidents etc.), the inclination to-
wards hypomanic or psychotic state as well as impulsi-
vity and aggression49,50. As significant suicide risk factors
and being particularly inherent in bipolar disorder the
affective instability, impulsivity and aggressiveness have
given the mood stabilizing medications special role in
treatment of bipolar disorder and elimination of suicidal
risk. Lithium, the medication used in psychiatry since
year 1949 as mood stabilizer, had been firstly recognized
for anti-suicidal potential. Therapeutic effectiveness in
bipolar disorder does not necessary imply drug efficiency
in reducing suicidal risk. The lithium has been proven in
reducing suicidal risk in bipolar disorder51,52. Ten years
ago there has been growing evidence, based on parallel
studies, on how other mood stabilizing drugs particularly
anticonvulsants (divalporex, carbamazepin) show almost
equal potential in reducing suicidal risk. The suicidal be-
haviour, after therapy withdrawal, had increased 16
times equally in patients trea- ted with lithium and in pa-
tients taking anticonvulsants53,54. Bipolar patient´s who
are being, for whatever reason, treated only with antide-
pressants have particularly high suicide risk and should
be monitored during treatment. Yerevanian et al., in year
2007, have been comparing patient groups on mood sta-
bilizing drugs (lithium, divalporex, carbamazepin) with
the groups taking mood stabilizing drug + antidepres-
sants and just antidepressants54. Key findings of this
study were, the suicidal behavior in patients on com-
bined therapy of mood stabilizers and antidepressants
was 2–3 times more often than in those who received
only mood stabilizer, and as much as 6–10 times more
frequent in the group who had received only antidepres-
sants55. Likewise, often necessary appliance of antipsy-
chotics in bipolar disorder requires careful selection and
monitoring of these patients. The suicide risk in patients
who have been receiving combination of antipsychotics
and mood stabilizers becomes 5 times higher and in
those receiving only antipsychotics as much as 10 times
higher than in bipolar patients soley on mood stabi-
lizers56. In this case, the most suitable drug combination
has expected to be mood stabilizers and second genera-
tion antipsychotics, particularly ones with low potential
of inducing akathisia and pharmacologic depression. In
refractory cases with obvious suicidal risk are best com-
bined clozapine and mood stabilizer. It must not be for-
gotten, the possibility of pharmacotherapy in reducing
and eliminating suicide risk has been limited with the
fact suicidality being complex cross-category biopsycho-
social phenomenon. The bipolar patients should also be
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given, besides pharmacotherapy, structured psychosocial
treatment or broader psychotherapeutic support with
psychosocial intervention especially during period of pro-
longed treatment57.
Conclusion
There is no unique theoretic explanation or therapeu-
tic method for prevention of suicidal behaviour. The
pharmacotherapy of suicidal behavior has limited role
for mentally ill patients. This role has been primarily
achieved by reducing and mitigating the suicide risk
through rational and individually adjusted pharmaco-
therapy focused on effective, safe and tolerable treat-
ment. During treatment of depressive disorder, the anti-
depressants in general and especially SSRI-s, if properly
implemented reduce risk of suicide. Caution is usually
advised in the first few weeks, and in children and ado-
lescents in the first months of therapy, because of initial
uneven antidepressant effect on specific aspects of de-
pressive disorder with possible transient pharmacogenic
potentiation of suicidal risk. The pharmacodynamic fea-
tures of second generation antipsychotics have ensured
treatment of schizophrenia with: good efficiency, dopa-
mine-serotonin concept of action with less akathisia and
pharmacogenic depression, better affective stability and
cognitive functioning followed by enhanced tolerability
and compliance. The clozapine stands as an exception for
it´s anti-suicidal potential. It has good anti-aggression
and antidepressive action, rarely causes akathisia and is
well tolerated therefore it has been recommended as the
drug of choice for alleviation of suicidal risk in schizo-
phrenia. The lithium has been proven for reduction of
suicidal risk in patients with bipolar disorder. Ten years
ago, based on comparative studies, growing evidence
highlighted how some mood stabilizers from the group of
anticonvulsants (eg. divalporex and carbamazepine) were
equally powerful in reducing suicidal risk. If antidepres-
sants or antipsychotics had been prescribed for the bipo-
lar disorder, then it was recommended to prescribe mood
stabilizer with them. In addition to pharmacotherapy, in
all three diagnostic groups was recommended, to provide
a structured psychosocial treatment or psychotherapeu-
tic support with psychosocial interventions, particulary
during phase of prolonged treatment.
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FARMAKOTERAPIJA SUICIDALOG PONA[ANJA OBOLJELIH OD DEPRESIJE,
SHIZOFRENIJE I BIPOLARNOG POREME]AJA
S A @ E T A K
Farmakoterapija suicidalnog pona{anja je za klini~ara vrlo zahtjevna i ima ograni~enu ulogu u sveukupnoj pre-
venciji suicida oboljelih od mentalnih poreme}aja, jer suicidalnost nadilazi dijagnosti~ku podjelu i slijedi vlastitu psiho-
patolo{ku dinamiku. Ta se uloga najve}im dijelom ostvaruje ubla`avanjem i uklanjanjem rizika suicidalnosti putem
racionalne i individualno prilago|ene farmakoterapije usmjerene na u~inkovito, sigurno i podno{ljivo lije~enje. Treba
ipak voditi ra~una o neurobiologiji suicidalnosti koja je odre|ena genetskim i epigentskim faktorima, disfunkcijom
neurotransmitorskog i neuroendokrinog sustava i sustava odgovora na stres. Zato farmakoterapijski pristup usmjeren
na prevenciju i uklanjanje suicidalnosti treba prilagoditi kako o op}im tako i za dijagnozu specifi~nim faktorima rizika.
Premda je suicidalnost transkategorijski fenomen, od izuzetne je va`nosti postavljanje pravilne dijagnoze, jer ista sku-
pina psihofarmaka ili ~ak isti psihofarmak, kod jedne dijagnosti~ke kategorije mo`e ubla`iti suicidalnost, a kod druge je
potencirati. Zato rezultate nekih epidemiolo{kih studija o smanjenju stope suicida nakon porasta potro{nje antide-
presiva, klini~ar treba uzeti s rezervom. Detaljnijom analizom dobivenih podataka, mo`e se primijetiti kako ipak nije
svejedno koje antidepresive dajemo kojim bolesnicima, u kojoj dobi i u kojoj fazi bolesti. FDA posebno upozorava na
mogu}nost porasta rizika od suicidalnog pona{anja pri primjeni antidepresiva kod djece i adolescenata. Op}enito uzev-
{i, serotoninergi~ka sredstva imaju neutralni ili blago protektivni u~inak na pojavu suicidalnog pona{anja dok noradre-
nergi~ka sredstva mogu imati i aktivacijski u~inak, odnosno ~ak pogor{ati suicidalnost u odre|enoj fazi poreme}aja. To
ne zna~i da kod konkretnog bolesnika, noradrenergi~ki ili dualni antidepresiv, ordiniran u pravo vrijeme i u pravoj dozi,
ne}e imati dobar antisuicidalni u~inak. Nadalje, primjena antidepresiva kod osoba s bipolarnim poreme}ajem, mo`e
tako|er imati aktivacijski u~inak na suicidalno pona{anje. Zato inzistiranje na ve}oj osjetljivosti za dijagnostiku bipo-
larnog poreme}aja i na {iroj primjeni stabilizatora raspolo`enja, samih ili u kombinaciji s drugim psihofarmacima, ima
zna~ajnu ulogu u spre~avanju i uklanjanju suicidalnog pona{anja u toj dijagnosti~koj kategoriji. Pritom se kao posebno
pogodni za prevenciju i uklanjanje suicidalnog pona{anja navode litij i natrijev valproat, ali i neki drugi stabilizatori
raspolo`enja. Poseban problem predstavlja farmakoterapija suicidalnosti u oboljelih od shizofrenije. Premda je klozapin
potvr|en kao sredstvo s antisuicidalnim u~inkom, taj lijek ne spada u prvu terapijsku liniju i ne mo`e biti op}e rje{enje
za problem suicidalnosti u shizofrenih. Farmakoterapija suicidalnog pona{anja ostaje za klini~ara i dalje usko vezana uz
umije}e racionalne i individualno prilago|ene primjene psihofarmaka, popra}ene odgovaraju}om psihoterapijskom po-
dr{kom.
